Some AI summarised TDP43 information in relation to Alzheimer's.
The role of TDP-43 in Alzheimer's disease (AD) is complex and fascinating, but not yet fully understood. While initially considered separate entities, research suggests TDP-43 pathology might play a significant role in AD progression and severity.
Here's a breakdown of what we know so far:What is TDP-43?TDP-43 is a protein normally found in the nucleus of cells, where it helps regulate gene expression. However, in certain neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), abnormal clumps of TDP-43 form in the cytoplasm of neurons, leading to cell death and tissue damage.
TDP-43 in ADrevalence: Up to 57% of AD brains show TDP-43 pathology, often in limbic regions crucial for memory and emotion.
Impact: AD patients with TDP-43 tend to have worse cognitive decline, more severe brain atrophy, and faster disease progression.
Interactions: TDP-43 can interact with the classic hallmarks of AD, amyloid plaques and tau tangles, potentially influencing their formation and effects.Genetics: The APOE4 gene, a major risk factor for AD, is also associated with increased TDP-43 pathology.
Key questions remain:Cause and effect: Does TDP-43 contribute to AD development, or is it a secondary consequence?Mechanisms: How exactly does TDP-43 interact with amyloid and tau, and how does it impact brain function?
Therapeutic potential: Can targeting TDP-43 pathology offer new avenues for AD treatment?
Current research:Ongoing research aims to answer these questions and explore the potential of targeting TDP-43 in AD treatment strategies. Investigating the complex interplay between TDP-43 and other disease mechanisms holds promise for developing more effective interventions for AD patients.
Remember, this is an evolving field of research, and our understanding of TDP-43 in AD is constantly being refined. However, the growing body of evidence suggests it plays a significant role in the disease, making it a crucial target for future advancements in diagnosis, treatment, and prevention.
- Forums
- ASX - By Stock
- PAA
- The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-124
-
-
- There are more pages in this discussion • 1,301 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.0¢ |
Change
-0.005(2.56%) |
Mkt cap ! $92.41M |
Open | High | Low | Value | Volume |
21.0¢ | 21.0¢ | 19.0¢ | $165.4K | 836.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 417395 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.5¢ | 103291 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 417395 | 0.190 |
4 | 88546 | 0.185 |
7 | 258662 | 0.180 |
8 | 377473 | 0.175 |
9 | 181233 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.195 | 103291 | 3 |
0.200 | 191216 | 3 |
0.205 | 40000 | 1 |
0.210 | 220211 | 6 |
0.215 | 254820 | 7 |
Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
BM8
BATTERY AGE MINERALS LTD
Nigel Broomham, CEO
Nigel Broomham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online